Pricing Log in Create free account
Friday 6 November 2026 Export ACB’s income statement to Excel — free account

Aurora Cannabis Inc.

ACB Healthcare Drug Manufacturers Specialty & Generic

Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025.

Revenue
−31.2%
EPS
+75.0%
Free cash flow
−293.6%
Total debt
−82.5%

Quarter to June 2026, against a year earlier

5.23 0.04 +0.77%
Market cap
$341.2M
P/E
0.0×
Fwd P/E
−52.4×
Dividend yield
—
F-score
4/9
Altman Z
−12.34
Beneish M
−2.53
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 341.19
Revenue ttm 209.97
Net income ttm (31.33)
Free cash flow ttm (36.10)
Net debt Q (95.56)
Valuation
P/E 0.00
Forward P/E (52.40) (negative: loss-making)
Price / sales 1.53
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.84
Financial health
Current ratio Q 5.36 (at or above 1.5: strong)
Debt / equity Q 0.03 (at or below 0.5: strong)
Interest coverage Q (18.82)
Growth
Revenue growth Q −31.15% (below 0%: shrinking)
Operating income growth Q +56.87% (above 0%: growing)
EPS, this year +85.11% (at or above 15%: strong)
EPS, next year A +150.30% (at or above 15%: strong)
Revenue, next year A −9.19% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +27.04% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.3×, against a ten-year median of 6.6×; over the ten years it ranged from 0.3× in 2024 to 1,016× in 2018.
P/S against its own 10 years 33.80%
10-year low 10-year high
P/B against its own 10 years 55.51%
10-year low 10-year high
EV/Sales against its own 10 years 35.46%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 136 134 119 108
Receivables 34 31 32 30
Inventory 138 172 127 135
Other 2 0 1 2
316 344 288 284
2024 2025 2026 Q'26
Payables 43 53 37 41
ST’ Debt 39 15 — —
Other 4 1 2 2
92 80 48 53

Compound Annual Growth %

10y 5y 3y
Sales 70.99% 3.92% 9.78%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 54.99% (25.28%) 0.46%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate −0.13 Actual 0.04

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 0.03 0.09 Beat by 0.06
Dec 2025 0.00 0.09 Beat by 0.09
Mar 2026 −0.07 0.07 Beat by 0.14
Jun 2026 −0.13 0.04 Beat by 0.17
Sep 2026 −0.03 — Reports 12 November 2026

EPS $

Sep Dec Mar Jun Year
’26 — — — (0.05) —
’26 (0.66) 0.02 (0.72) (0.20) (1.55)
’25 (0.16) 0.41 (0.30) 0.10 0.03
’24 (0.10) (0.40) (0.30) — (1.13)
’23 (1.30) (1.50) 1.00 (0.60) (0.62)
’22 (0.50) (3.00) (37.30) (2.03) (63.16)
’21 (6.90) (13.40) (6.70) (0.55) (32.08)
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 — — — 49 —
’26 66 68 28 71 232
’25 59 63 63 61 247
’24 47 47 50 — 200
’23 38 45 53 56 175
’22 48 48 40 39 175
’21 51 52 44 45 191
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (3) — — — —
’26 7 (29) 12 0 (10)
’25 6 (18) 21 3 12
’24 — (23) (3) (16) (51)
’23 (8) (24) (44) — (87)
’22 (87) (18) (17) (31) (87)
’21 (164) (81) (51) (49) (164)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (7) — — — —
’26 4 (33) 9 (4) (25)
’25 3 (21) 18 0 (1)
’24 — (26) 1 (20) (54)
’23 (10) (24) (35) — (87)
’22 (97) (16) (26) (23) (97)
’21 (191) (93) (58) (59) (191)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Jun ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 14 43 187 208 191 175 175 200 247 232 210 +37.0% 211 231 253 +2.9%
Gross margin, % 88.87 64.48 64.46 (12.03) (8.79) 9.59 (27.59) 48.64 54.65 42.62 49.74 (46.2) pt
EBT (13) 61 (248) (2,523) (546) (1,359) (222) (44) 15 (41) (30) +13.6%
EBT margin, % (95.56) 140.09 (132.38) (1,213.27) (285.34) (777.14) (126.63) (22.05) 5.94 (17.63) (14.06) +77.9 pt
Net income (10) 55 (225) (2,461) (541) (1,357) (199) (44) 11 (42) (31) +17.7%
Per share, $
Per share, $ Revenue 5.86 11.35 22.13 21.49 11.32 8.14 0.54 4.64 4.50 4.09 3.40 (3.9%)
Earnings (4.21) 14.24 (26.59) (255.10) (32.08) (63.16) (0.62) (1.13) 0.03 (1.55) (1.41) (10.5%)
Cash flow (3.41) (16.80) (17.16) (26.04) (9.72) (4.04) (0.27) (1.17) 0.21 (0.17) (0.33) (28.2%)
Capex (10.53) (56.70) (36.98) (27.07) (1.56) (0.46) 0.00 (0.08) (0.22) (0.27) (0.26) (33.3%)
Free cash flow (13.94) (73.49) (54.14) (53.11) (11.28) (4.50) (0.27) (1.26) (0.01) (0.45) (0.59) (31.8%)
Book value 71.00 321.48 391.88 163.87 94.05 24.35 1.13 10.32 7.98 6.53 6.17 (23.3%)
Shares, m 2 4 8 10 17 21 323 43 55 57 58 +42.6%
Valuation, ×
Valuation, × P/E 0.00 1,381.62 0.00 0.00 0.00 0.00 0.00 0.00 73.41 0.00 0.00 145.5
P/S 330.36 741.08 424.53 57.09 78.44 16.22 1.07 0.93 0.98 0.80 1.53 165.1
P/B 27.20 26.17 23.98 7.49 9.44 5.42 0.54 0.42 0.55 0.50 0.84 10.2
EV/Sales 324.21 742.05 425.67 58.39 78.24 15.20 0.79 0.62 0.72 0.53 1.28 164.6
EV/FCF 0.00 (90.74) (101.55) (12.56) (37.36) (16.48) (0.92) (2.30) (302.77) (4.89) (7.46) (57.0)
Cash, $m
Cash, $m Operating cash flow (8) (64) (145) (252) (164) (87) (87) (51) 12 (10) (20) +2.4%
Capex (24) (217) (313) (262) (26) (10) (9) (3) (12) (16) (16) (4.9%)
Free cash flow (32) (281) (458) (514) (191) (97) (87) (54) (1) (25) (36) (2.7%)
Balance, $m
Balance, $m Working capital 128 114 172 110 429 474 179 224 264 239 231 +7.2%
Net debt (84) 42 214 270 (40) (179) (55) (62) (62) (106) (96) +2.7%
Shareholders’ equity 165 1,231 3,316 1,585 1,591 523 365 446 437 370 381 +9.4%
Returns, %
Returns, % ROA (6.53) 6.48 (7.76) (79.21) (26.41) (93.92) (25.69) (7.38) 0.26 (16.82) (15.19) (10.3) pt
ROIC (6.47) (4.09) (4.20) (12.33) (8.90) (33.21) 0.00 (5.60) 0.59 (7.98) (5.58) (1.5) pt
ROE (11.52) 8.12 (9.66) (100.72) (34.17) (128.39) (44.89) (11.98) 0.37 (21.82) (19.85) (10.3) pt
People
People Employees 171 64 2,779 2,731 1,761 1,338 — 1,073 1,130 1,028 — +22.1%
Revenue/emp, $m 0.08 0.68 0.07 0.08 0.11 0.13 0.00 0.19 0.22 0.23 — +12.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

Aurora Cannabis Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TKNO Alpha Teknova, Inc. $486.2M — (loss-making) — (loss-making) +21.52% (above 0%: growing) n/m +40.94% (above 0%: growing) 37.99% (25.24%) Compare
AQST Aquestive Therapeutics, Inc. $460.0M — (loss-making) — (loss-making) −40.99% (below 0%: shrinking) n/m +40.78% (above 0%: growing) 52.28% (191.46%) Compare
TLRY Tilray Brands, Inc. $415.3M — (loss-making) — (loss-making) +22.74% (above 0%: growing) n/m −159.66% (below 0%: shrinking) 30.14% (9.35%) Compare
KMDA Kamada Ltd. $396.3M 18.1× — (loss-making) +22.72% (above 0%: growing) +23.08% (above 0%: growing) +165.71% (above 0%: growing) 40.91% 17.32% Compare
ACB Aurora Cannabis Inc. $341.2M — (loss-making) — (loss-making) −31.15% (below 0%: shrinking) n/m −293.56% (below 0%: shrinking) 52.73% (12.92%)
EBS Emergent Biosolutions Inc. $300.8M — (loss-making) — (loss-making) −52.40% (below 0%: shrinking) n/m +1,892.98% (above 0%: growing) 26.55% (33.91%) Compare
CGC Canopy Growth Corporation $283.5M — (loss-making) — (loss-making) +12.41% (above 0%: growing) n/m −117.60% (below 0%: shrinking) 27.40% (27.24%) Compare
ANIK Anika Therapeutics Inc. $258.7M — (loss-making) 599× +15.56% (above 0%: growing) n/m +61.58% (above 0%: growing) 65.15% 9.06% Compare
BIOA BioAge Labs, Inc. $254.3M — (loss-making) — (loss-making) −85.49% (below 0%: shrinking) n/m −92.81% (below 0%: shrinking) 100.00% (12,554.03%) Compare
Median of peers $348.6M — — +13.99% — +40.86% 39.45% (26.24%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Aurora Cannabis Inc. (ACB) Latest News

5 Nov

Impact 4 · · Business Wire

4 Nov

Impact 4 · · Zacks

3 Nov

Impact 4 · · Proactive Investors
Impact 4 · · MT Newswires
Impact 4 · · Stocktwits
Impact 4 · · Moby
Impact 4 · · Business Wire
Impact 3 · · CNW Group

29 Oct

Impact 3 · · Business Wire

27 Oct

Impact 4 · · CNW Group
Impact 3 · · Zacks

26 Oct

Impact 4 · · PR Newswire

23 Oct

Impact 4 · · Zacks

20 Oct

Impact 4 · · MarketBeat

19 Oct

Impact 4 · · CNW Group
Impact 4 · · PR Newswire

14 Oct

Impact 4 · · CNW Group
Impact 4 · · PR Newswire
Impact 3 · · Simply Wall St.

13 Oct

Impact 4 · · Moby

12 Oct

Impact 4 · · The Motley Fool

9 Oct

Impact 4 · · MarketBeat

8 Oct

Impact 4 · · CNW Group
Impact 4 · · PR Newswire
Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

6 Oct

Impact 5 · · CNW Group
Impact 4 · · PR Newswire
Impact 4 · · CNW Group
Impact 4 · · MarketBeat
stockrow.com/ACB · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com